RT Journal Article
SR Electronic
T1 The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.10.22269967
DO 10.1101/2022.02.10.22269967
A1 Racine, Étienne
A1 Boivin, Guy
A1 Longtin, Yves
A1 McCormack, Deirde
A1 Decaluwe, Hélène
A1 Savard, Patrice
A1 Cheng, Matthew P.
A1 Hamelin, Marie-Ève
A1 Tadount, Fazia
A1 Adams, Kelsey
A1 Bourdin, Benoîte
A1 Nantel, Sabryna
A1 Gilca, Vladimir
A1 Corbeil, Jacques
A1 De Serres, Gaston
A1 Quach, Caroline
YR 2022
UL http://medrxiv.org/content/early/2022/02/10/2022.02.10.22269967.abstract
AB Background Understanding the immune response to natural infection by SARS-CoV-2 is key to pandemic management, especially in the current context of emerging variants. Uncertainty remains regarding the efficacy and duration of natural immunity against reinfection.Method We conducted an observational prospective cohort study in Canadian healthcare workers (HCWs) with a history of PCR-confirmed SARS-CoV-2 infection to : (i) measure the average incidence rate of reinfection and (ii), describe the serological immune response to the primary infection.Results We detected 5 cases of reinfection over 14 months of follow-up, for a reinfection incidence rate of 3.3 per 100 person-years. Median duration of seropositivity was 420 days in symptomatics at primary infection compared to 213 days in asymptomatics (p<0.0001). Other variables associated with prolonged seropositivity for IgG against the spike protein included age 55 and above, obesity, and non-Caucasian ethnicity.Summary Among healthcare workers, the incidence of reinfection with SARS-CoV-2 following a primary infection remained rare, although our analysis predates the circulation of the Omicron variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Canadian Institutes of Health Research (Funding reference: VR2172712) and the COVID19 Immunity Task Force/Public Health Agency of Canada. CQ, GB and JC are chairholders through the Canada Research Chair program. YL, HD, MPC are supported through the Fonds de recherche du Quebec-Sante clinician scientist program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHU Sainte-Justine Research Ethics Committee (MP-21-2021-3035) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors